Budget Impact of Sequential Treatment with Biologics, Biosimilars, and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Thai Patients with Rheumatoid Arthritis
Background: Targeted treatment of rheumatoid arthritis (RA) includes biological DMARDs (bDMARDs) and JAK inhibitors (JAKi). These agents are recommended at the same level on the basis of their efficacy and safety data. However, no local evidence of the impact of RA treatment regimens on total budget...
Saved in:
Main Authors: | Manathip Osiri, Piyameth Dilokthornsakul, Sasitorn Chokboonpium, Pichaya Suthipinijtham, Ajchara Koolvisoot |
---|---|
Other Authors: | Siriraj Hospital |
Format: | Article |
Published: |
2022
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/77912 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Similar Items
-
Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
by: Prawjaeng J.
Published: (2023) -
Rate and causes of noncompliance with disease-modifying antirheumatic drug regimens in patients with rheumatoid arthritis
by: Wanruchada Katchamart, et al.
Published: (2020) -
Cost-Utility Analysis of Biologic Disease-Modifying Antirheumatic Drugs for Patients With Psoriatic Arthritis in Thailand
by: Dilokthornsakul P.
Published: (2023) -
Cost-Utility Analysis of Biologic Disease-Modifying Antirheumatic Drugs for Patients With Psoriatic Arthritis in Thailand
by: Dilokthornsakul P.
Published: (2023) -
Cost-Utility Analysis of Biologic Disease-Modifying Antirheumatic Drugs for Patients With Psoriatic Arthritis in Thailand
by: Dilokthornsakul P.
Published: (2023)